{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-237199","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2026-05-22T21:24:41+00:00","discovered_at":"2026-05-22T21:26:00.257527+00:00","generated_at":"2026-05-22T21:28:16.063597+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Maze Therapeutics SVP Finance Amy Bachrodt to resign effective June 1, 2026","bullets":["Amy Bachrodt resigns as SVP, Finance, effective June 1, 2026.","Resignation not related to any disagreement with the company.","CFO Misbah Tahir will assume principal accounting officer role."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-237199","json":"https://secwatch.observer/filing/0001193125-26-237199.json","markdown":"https://secwatch.observer/filing/0001193125-26-237199.md","text":"https://secwatch.observer/filing/0001193125-26-237199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/d909749d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:28:16.063597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bd3306082","claim":"Misbah Tahir changed role as Chief Financial Officer and principal accounting officer at Maze Therapeutics, Inc..","evidence_excerpt":"Misbah Tahir, the Company’s Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt’s departure.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm","confidence":0.9},{"claim_id":"c95279582e","claim":"Amy Bachrodt departed as Senior Vice President, Finance at Maze Therapeutics, Inc..","evidence_excerpt":"On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}